secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2026-05-21T21:12:40+00:00
Accession:  0001193125-26-234882
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics schedules June 10 vote on Series B conversion that would trigger change of control
--------------------------------------------------------------------------------

- Annual meeting on June 10, 2026 to vote on conversion of Series B Preferred Stock into common stock.
- Conversion would issue ~24.4M shares, representing >20% of outstanding and result in change of control per Nasdaq rules.
- Pro forma shows reclassification of $321.9M from preferred stock to equity; net loss per share improves from $131.45 to $6.62.
- Conversion contingent on stockholder approval; if approved, occurs three business days after vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526234882/0001193125-26-234882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526234882/d162035d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-234882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer